Wall Street analysts expect DENTSPLY SIRONA Inc. (NASDAQ:XRAY) to announce $1.06 billion in sales for the current quarter, Zacks reports. Nine analysts have made estimates for DENTSPLY SIRONA’s earnings, with the highest sales estimate coming in at $1.08 billion and the lowest estimate coming in at $1.03 billion. DENTSPLY SIRONA posted sales of $996.50 million during the same quarter last year, which suggests a positive year-over-year growth rate of 6.4%. The company is scheduled to issue its next earnings results on Friday, February 16th.

On average, analysts expect that DENTSPLY SIRONA will report full year sales of $1.06 billion for the current fiscal year, with estimates ranging from $3.93 billion to $3.99 billion. For the next financial year, analysts anticipate that the business will report sales of $4.16 billion per share, with estimates ranging from $4.08 billion to $4.23 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $978.99 million. During the same period in the previous year, the firm earned $0.66 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was up 5.8% on a year-over-year basis.

Several equities research analysts have issued reports on the stock. HC Wainwright downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price objective for the company. in a research note on Thursday, November 30th. Deutsche Bank started coverage on shares of DENTSPLY SIRONA in a research note on Friday, December 8th. They issued a “buy” rating and a $81.00 target price for the company. Barrington Research upgraded shares of DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $73.00 target price for the company in a research note on Monday, November 6th. Morgan Stanley restated an “overweight” rating and issued a $69.00 target price (up from $67.00) on shares of DENTSPLY SIRONA in a research note on Friday, October 6th. Finally, J P Morgan Chase & Co upgraded shares of DENTSPLY SIRONA from a “neutral” rating to an “overweight” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $68.83.

Shares of DENTSPLY SIRONA (NASDAQ:XRAY) opened at $64.99 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 2.32. DENTSPLY SIRONA has a 52 week low of $52.53 and a 52 week high of $68.98. The stock has a market cap of $14,933.98, a P/E ratio of 25.90, a price-to-earnings-growth ratio of 2.58 and a beta of 1.31.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 12th. Stockholders of record on Friday, December 29th will be given a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 0.54%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -10.09%.

In other news, insider Mark Thierer bought 77,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was bought at an average cost of $66.04 per share, for a total transaction of $5,085,080.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. Company insiders own 1.99% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Korea Investment CORP lifted its position in shares of DENTSPLY SIRONA by 139.9% in the second quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock worth $139,000 after purchasing an additional 1,251 shares in the last quarter. Beach Investment Management LLC. purchased a new stake in shares of DENTSPLY SIRONA in the second quarter worth approximately $3,057,000. Wetherby Asset Management Inc. lifted its position in shares of DENTSPLY SIRONA by 0.6% in the second quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock worth $324,000 after purchasing an additional 30 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of DENTSPLY SIRONA by 2.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 729,311 shares of the medical instruments supplier’s stock worth $47,289,000 after purchasing an additional 18,732 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of DENTSPLY SIRONA by 8.6% in the second quarter. First Trust Advisors LP now owns 323,240 shares of the medical instruments supplier’s stock worth $20,959,000 after purchasing an additional 25,544 shares in the last quarter. Institutional investors own 96.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/13/dentsply-sirona-inc-xray-expected-to-post-quarterly-sales-of-1-06-billion.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.